.svg)
.jpg)
The global gut health supplements market was valued at USD 19.98 billion in 2025 and is projected to reach USD 36.57 billion by 2033. This rapid growth is reshaping how every supplement manufacturer approaches product design, delivery, and differentiation.
Gut health is no longer limited to basic probiotic capsules. The category now includes enzymes, minerals, postbiotics, and targeted formulations designed for specific outcomes such as digestion support, microbiome balance, and metabolic health. This shift is pushing manufacturers to move beyond ingredient sourcing and into delivery science.
As a result, the role of a supplements manufacturer has expanded significantly. It now involves selecting the right dosage format, optimising release profiles, and ensuring stability across increasingly complex formulations. Delivery systems have become central to product performance, not just a downstream consideration.
Consumer expectations are also driving this shift. Convenience, ease of administration, and faster perceived efficacy are driving interest in alternative formats. This is where capsules and oral thin films come into sharper focus as two distinct yet complementary approaches.
A pharmaceutical manufacturer working in the nutraceutical space plays a critical role in translating formulation intent into a viable product. This includes evaluating how different delivery formats interact with ingredient characteristics, stability requirements, and absorption pathways.
Capsules remain one of the most established formats across nutraceuticals and generic drug manufacturing. They offer formulation flexibility and are widely accepted across global markets. Oral thin films, by contrast, represent a more recent advancement, designed to address specific limitations of conventional oral dosage forms.
Both formats serve gut health applications, but in different ways. Capsules typically support formulations that require protection through the gastrointestinal tract, such as probiotics. Oral thin films enable faster release and absorption for certain actives by leveraging the oral mucosa, lining of the mouth.
Format selection is therefore a strategic decision. It directly affects bioavailability, onset of action, stability, and user experience. As highlighted in Health Supplements That Keep Your Gastric Problems at Bay, the effectiveness of a gut health product is closely linked to how well its delivery system aligns with the intended therapeutic outcome.
Capsules continue to be a core format for any supplements manufacturer, particularly in gut health formulations that require precision, protection, and flexibility.
One of their primary advantages lies in ingredient stability. Probiotic strains, for instance, are highly sensitive to moisture, temperature, and oxygen exposure. Capsules provide a controlled environment that helps preserve viability until the point of release. This is critical for ensuring that the product delivers what is stated on the label.
Capsules also offer high dosing capacity, making them suitable for multi-strain probiotic blends and formulations that combine prebiotics, enzymes, and micronutrients. Their ability to accommodate powders, pellets, and even liquid fills allows for complex formulation strategies within a single dosage unit.
From a release perspective, capsules can be engineered for targeted delivery. Enteric coatings or modified-release systems enable actives to bypass the stomach and release in the intestine, which is particularly relevant for microbiome-focused products.
Capsules rely on gastrointestinal processes for disintegration and absorption which influences onset time. This may not be ideal for actives that require rapid systemic availability. However, for many gut health applications, this controlled and site-specific release is precisely what makes capsules effective.
Oral thin films are gaining traction among pharmaceutical manufacturers and supplements manufacturer partners looking to address evolving consumer and formulation needs.
These films are designed as ultra-thin polymer strips that dissolve rapidly in the oral cavity. Depending on the formulation design, actives may be absorbed either through the mucosal lining or after swallowing.
Their strongest advantage lies in rapid disintegration and onset. For actives that benefit from quick absorption, oral thin films provide a more direct pathway compared to traditional oral dosage forms.
They also offer enhanced convenience and compliance. No water is required, and administration is simple, making them suitable for on-the-go use and for populations that face difficulty swallowing capsules.
From a formulation perspective, oral thin films are particularly effective for specific categories of ingredients:
However, oral thin films also present formulation constraints. They are less suitable for high-dose or bulky ingredients and require careful control of moisture and packaging conditions. Stability of sensitive actives, especially live organisms, can be more challenging compared to capsules.
When capsules are the better choice:
Capsules work well for formulations that require high dosing, multi-ingredient combinations, or protection of sensitive actives such as probiotics. They also support targeted intestinal delivery.
When oral thin films are the better choice:
Oral thin films are effective for low-dose, fast-acting actives where rapid absorption and convenience are priorities.
The decision ultimately depends on aligning the delivery format with formulation goals, ingredient characteristics, and the intended user experience. A capable supplements manufacturer evaluates these parameters early to ensure consistency between product design and performance.
For pharmaceutical and nutraceutical brands, the choice of supplements manufacturer directly influences product quality, scalability, and market success.
A pharmaceutical manufacturer with capabilities across multiple delivery platforms enables greater flexibility in formulation strategy. Integration with generic drug manufacturing expertise strengthens process control, regulatory readiness, and batch consistency.
ZIM Labs brings this integrated approach through capabilities in oral thin films, pellets, granules, and pre-formulation intermediates. This allows partners to develop and scale differentiated gut health products while maintaining alignment between formulation intent and commercial execution.
A well-aligned partnership ensures that delivery format, formulation design, and manufacturing processes work together to deliver consistent, high-quality outcomes.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
